Alexion Pharmaceuticals, until recently seen as one of biotech’s biggest success stories, is eliminating roughly 600 jobs and moving its headquarters to Boston amid federal investigations and pressure to cut costs.
The company made its name on Soliris, a treatment for rare diseases that — at a cost of about $700,000 a year — is also the world’s most expensive drug. But after a series of pipeline disappointments and an ill-advised $8.4 billion acquisition, Alexion is facing an uncertain future.
About the Author Reprints
Thanks for the update, can I set it up so I get an email whenever you write a new update?
http://blog1.de/horheu/3779173/A+Little+Something+To+Talk+About+–+Bathroom+Construction.html
9412685810
Moving to the Boston area is great. The CEO should keep on top to know if their leaders are acting in the interest of the company. Politically motivated decisions to safeguard themselves in case something happens to their job could be dangerous.